Peptide Industry Statistics 2026: Regulation, Research, Market, Testing, and Use

How is the FDA regulating research peptides in 2026?

The FDA classes research peptides sold with health claims as unapproved new drugs, and the compounding route for the popular ones is closing. The record below is the agency's own.

Warning letters. On August 24, 2026, FDA issued warning letters to at least five online peptide sellers on the same day, each cited for unapproved new drugs and misbranding (FDA warning letter database, posted September 1, 2026). In its March 31, 2026 letter to Gram Peptides, FDA stated that the products were unapproved new drugs under section 505(a) after reviewing the site from January to March 2026, research-use labeling included (FDA). On March 3, 2026, FDA announced 30 warning letters in one round to telehealth companies over compounded GLP-1 marketing (FDA press announcement).

A note on counts. Figures such as "50 or more warning letters in September 2025" circulate on law-firm alerts and industry blogs. FDA publishes each letter but no yearly total, and its search tool cannot be cited as a count. We confirmed individual letters dated September 9, 2025 and through August 2026, so a large batch is consistent with the record. Count any total as an estimate until FDA publishes one.

The 503A bulks lists. FDA's May 14, 2026 list places one peptide in Category 1, vasoactive intestinal peptide, beside about 48 non-peptide substances (FDA 503A bulks list). Category 2, the substances FDA says raise significant safety risks, holds six entries, and Kisspeptin-10 is the only peptide, added September 29, 2023 (FDA). The same FDA page lists 12 peptides as nominated and then withdrawn from Category 2 in April 2026: AOD-9604, BPC-157, cathelicidin LL-37, DSIP, Epitalon, ipamorelin acetate, PEG-MGF, MOTS-c, Selank, Semax, thymosin alpha-1, and thymosin beta-4 (TB-500). The Federal Register notice of April 16, 2026 corroborates the change (Federal Register 2026-07361).

The advisory committee. FDA convened the Pharmacy Compounding Advisory Committee on July 23 and 24, 2026 to consider seven peptides for the 503A list: BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, and Epitalon, under docket FDA-2025-N-6895 (FDA meeting page). The docket closed July 22, 2026. In the staff briefing document, FDA wrote: "Accordingly, we propose not adding BPC-157 (free base) or BPC-157 acetate to the 503A Bulks List," citing incomplete physicochemical characterization and a lack of safety and immunogenicity data (FDA briefing document). FDA also stated it intends to consult the committee before the end of February 2027 on GHK-Cu (FDA).

Congress. The SAFE Drugs Act of 2025, H.R.6509, was introduced December 9, 2025 by Rep. Rudy Yakym and referred to Energy and Commerce (congress.gov). The Senate companion, S.3794, was introduced February 5, 2026 by Sen. Jim Banks and reported by the HELP Committee with a substitute amendment on July 27, 2026, Calendar No. 524 (congress.gov). Per the Congressional Research Service summary, the bill raises the allowed frequency for compounding a copy of a commercially available drug from FDA's current four prescriptions per month to 20 (CRS summary).

Prosecutions. On July 30, 2026, Matthew Kawa of Paradigm Peptides was sentenced to 5 years and 10 months in prison with $78,317.52 in restitution, joint with co-defendant Jennifer Stechkober, who received 16 months (DOJ, Northern District of Indiana). On April 1, 2026, a federal grand jury in Utah indicted Dr. Justin Bradley Watkins on eight counts for receiving and distributing misbranded peptides, BPC-157, TB-500, GHK-Cu, ipamorelin, and CJC-1295 among them (court docket via CourtListener). In an earlier case, a Nevada seller of the peptide PNC-27 paid a Chinese manufacturer more than $600,000 for product before pleading guilty to federal misbranding conspiracy (DOJ, Northern District of Alabama).

Imports. Import Alert 66-41, detention without physical examination of unapproved new drugs promoted in the US, was revised May 19, 2026 (FDA). FDA implemented the Green List of Import Alert 66-80, covering GLP-1 bulk drug substances, on September 5, 2025 (FDA).

Sport. The WADA 2026 Prohibited List, in force January 1, 2026, names BPC-157 under S0 and lists thymosin beta-4 and its derivatives, TB-500 by name, under S2.3, prohibited at all times (WADA). USADA gave triathlete Anthony McCauley four years of ineligibility from September 9, 2025 for possessing and using BPC-157 and TB-500 and promoting CJC-1295, ipamorelin, and tesamorelin to followers (USADA). Speedskater Kamryn Lute received a one-year sanction in 2024 after declaring a product containing BPC-157 (USADA). UFC athlete Cortney Casey accepted four months in 2023 after self-reporting BPC-157 (USADA).

How much clinical research exists on these peptides?

For most research peptides, very little in humans. The counts below come from ClinicalTrials.gov's public API on September 13, 2026, and each link reproduces the query. A registered study is not a completed one, and a mention is not a trial of that compound alone.

Two search notes. The string "TB-500" alone returns one study, so the table uses the compound's pharmacological name. "PT-141" alone returns four, so the table uses the INN bremelanotide. NAD+ is left out of the table because "nicotinamide adenine dinucleotide" returns 550 studies that span all of NAD biology, not one product.

Published papers. PubMed indexed 228 papers matching BPC-157 and 868 matching thymosin alpha-1 on September 13, 2026 (PubMed query, BPC-157; PubMed query, thymosin alpha-1).

What the reviews found. A 2026 review in The American Journal of Sports Medicine, led from UCLA, analyzed 565 studies of BPC-157, TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu. More than two-thirds were animal-only (UCLA Newsroom, September 2, 2026).

Approved peptide drugs. Since insulin in 1921, the FDA has authorized around 100 peptides (Al Musaimi, Biomolecules, February 2024). Between 2016 and 2024 alone, 34 FDA approvals were peptides, and one more, elamipretide, followed in 2025 (Pharmaceuticals, January 2026). The two counts use different windows and are not added together.

The next peptides through the pipeline. Lilly's TRIUMPH Phase 3 program for retatrutide has enrolled more than 5,800 participants, 2,339 of them in TRIUMPH-1 (Lilly press release via PR Newswire, May 21, 2026). Novo Nordisk's REDEFINE 1 and REDEFINE 2 trials of CagriSema, which contains cagrilintide, enrolled 3,417 and 1,206 adults (Novo Nordisk, December 18, 2025). For where that program stands, see Retatrutide in 2026: where the Phase 3 program stands.

How big is the approved peptide drug market?

Two companies' GLP-1 lines passed $60 billion in 2025 on their own filings. There is no need for a market report when the sellers publish the numbers.

Eli Lilly. Mounjaro earned $22.965 billion and Zepbound $13.542 billion in full-year 2025 (Lilly Q4 2025 release, SEC filing, February 4, 2026). In the second quarter of 2026, Mounjaro brought $9.943 billion and Zepbound $4.928 billion (Lilly Q2 2026 release, SEC filing, August 5, 2026).

Novo Nordisk. Ozempic sales were DKK 127,089 million and Wegovy DKK 79,106 million for 2025 (Novo Nordisk annual report, SEC 6-K, February 2026). In the second quarter of 2026, Ozempic sold DKK 31,375 million and injectable Wegovy DKK 19,484 million (Novo Nordisk Q2 2026, SEC 6-K, August 4, 2026).

Shortages that opened the compounding window. Tirzepatide injection entered the FDA drug shortage list December 15, 2022 and FDA declared the shortage resolved December 19, 2024 (FDA declaratory order). Semaglutide injection entered in March 2022 for Wegovy and August 2022 for Ozempic, and FDA declared it resolved February 21, 2025 (FDA declaratory order). FDA does not publish the quantity data that manufacturers submitted for those decisions.

How big is the gray market for research peptides?

No peer-reviewed estimate exists. We searched for one and found none. The peer-reviewed literature on the gray market describes availability, purity, and risk, and never a dollar figure. What does exist is one measured slice, crypto payments, from one private analytics firm.

Crypto flows, per Chainalysis. In its June 4, 2026 report, Chainalysis wrote that on-chain gray-market peptide sales passed a $100 million annual run rate. Quarterly inflows rose 159%, from $12 million in Q4 2025 to $32 million in Q1 2026, and the network was on pace for $39 million in Q2 2026 after six straight quarters of growth. After the "looksmaxxing" trend in late 2025, average monthly inflows quadrupled to $9.9 million, with peak months above $10 million. Wallets linked to the testing lab Janoshik received over $12 million for testing services since 2023. One Chinese manufacturer, Shanghai Sigma Audley, processed over $1 million in bitcoin and $3.59 million in stablecoins in one year as a fentanyl-precursor supplier before pivoting to peptides (Chainalysis). Chainalysis is a private company that sells blockchain analytics. Its figures cover crypto only, so card and bank payments, which most vendors also take, are outside the count.

The figures without a source. Two numbers about Peptide Sciences, the largest US vendor until it closed on March 6, 2026, appear all over the web. One is revenue of $7.4 million per month at closing. The other is a closure trigger of "50-plus warning letters." Every instance we found traces to a single private e-commerce analytics vendor, Grips Intelligence, quoted by blogs and law-firm pages, none of which links a report. No court filing, DOJ record, or company statement carries the revenue figure. We list it here because readers search for it, and we mark it as unsourced. If the figure is close to right, one vendor alone would have been near the whole crypto run rate Chainalysis measured, which is a reason to consider the gray market far larger than the crypto slice.

Court records with dollar values. The two DOJ cases above are the only federal records we found that state money: more than $600,000 paid to a manufacturer in the PNC-27 case, and $78,317.52 in restitution in the Paradigm Peptides case. Neither is a market figure. They are the floor of what a prosecutor could prove.

How pure are the peptides people actually buy?

Published purchase-and-test studies find frequent dose and purity misses, and the public per-lot record across vendors is thin. Outside sources first. Our own data follows, labeled.

Independent tests. For its April 13, 2026 article, The New Yorker bought peptides and had them tested through Finnrick and Krause Analytical. A BPC-157 vial contained lead, a TB-500 vial contained endotoxins, and a CJC-1295 vial from SwissChems contained less than 42% of the advertised dose. A MOTS-c sample from another seller tested 98% pure and held 87% of its labeled dose. Krause Analytical's director estimated that about 10% of the samples Finnrick sends him show serious anomalies of purity, dose, or sterility (The New Yorker).

Finnrick's public database. Finnrick reported 9,997 published tests as of September 3, 2026 (Finnrick methodology). Its retatrutide table rests on 3,694 tests across 256 vendors, tirzepatide on 2,401 tests across 190 vendors, and BPC-157 on 756 tests across 110 vendors (Finnrick products, tests through August 26, 2026).

Peer-reviewed test purchases. A 2024 study in the Journal of Medical Internet Research bought semaglutide from three illegal online pharmacies. Measured peptide concentration was 7.7%, 8.97%, and 14.37% against labels claiming 99% purity, while the semaglutide content per vial exceeded the label by 28.56% to 38.69%. Endotoxin was detected in all three samples at 2.1645 to 8.9511 EU/mg, and visual inspection failed 59% to 63% of packaging criteria (Ashraf et al., JMIR, November 2024).

A July 30, 2026 study in Pharmaceutical Research examined follow-on and compounded semaglutide and liraglutide. It found 44 impurities across eight compounded semaglutide products by LC-MS, 34 of them absent from the originator drug, and reported distinct impurity profiles and reduced physical stability in the follow-on products (Kopp et al., Pharmaceutical Research). The authors are Novo Nordisk employees, which readers should weigh. The study is open access and the methods are published.

Adverse event reports. As of May 31, 2026, FDA had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide (FDA, posted September 1, 2026).

Figures we chose not to repeat as fact. A "43% of Janoshik tests fail" statistic appears on several comparison blogs. It is not published on Janoshik's site. A preprint that reports 6,441 gray-market samples with failure rates of 41.6% to 71.1% exists on Preprints.org, labeled not peer reviewed. Both may prove right. Neither meets the bar for this page yet.

Curo's lot data, as a primary source. Our third-party lot testing table is archived as a citable dataset: 29 reports on 15 compounds, 22 certificates of analysis and 7 endotoxin tests, from three labs (BT Labs, ILS Labs, and Janoshik). Purity ranged from 99.31% to 99.9%. Identity was confirmed on 19 reports. All 7 endotoxin results fell under the 40 EU per vial limit (Curo research peptide lot testing dataset, Zenodo, DOI 10.5281/zenodo.22706906, CC BY 4.0). The underlying certificates and the method notes are on our quality and testing standard page, and a line-by-line reading guide is in How to read a peptide COA.

Across vendors. Peptide Source Tracker, a directory we operate and disclose as ours, listed 33 research peptide vendors as of August 29, 2026. Of those, 9 publish a certificate for every lot, 15 confirm third-party testing, and 4 are defunct, rebranding, or convicted (Peptide Source Tracker). A public certificate can be checked against the lab's own record. How to verify your lot walks through that check.

Who uses peptides, and how is demand changing?

GLP-1 use is measured by national polls every few months. Research-peptide use is not measured at all, apart from anti-doping cases and poison-center counts.

National surveys. In November 2025, 12% of US adults said they were currently taking a GLP-1 drug, up from 6% eighteen months earlier, and 18% said they had ever taken one (KFF). Gallup put current use for weight loss at 11% in mid-2026, up from 3% in 2024, with 15% reporting use at some point (Gallup, July 7, 2026). In February 2024, about three-quarters of Americans had heard at least a little about these drugs (Pew Research Center).

Prescriptions. In 2024, 26.5% of US adults with diagnosed diabetes used an injectable GLP-1, an estimated 6.9 million people (CDC/NCHS Data Brief 537, August 2025). Medicaid GLP-1 prescriptions rose from about 1 million in 2019 to over 8 million in 2024 (KFF, January 2026). In the commercial market, monthly GLP-1 prescription volume grew from 680,000 in January 2020 to 4.7 million in May 2025, and nearly 25% of diabetes patients had started a GLP-1 by early 2025, up from 3% four years earlier (IQVIA, November 2025).

Poison centers. America's Poison Centers managed 22,966 GLP-1 exposure cases from 2019 through 2025 and reports a nearly 1,500% rise in related calls since 2019 (America's Poison Centers). A national poison-data study counted 10,033 GLP-1 exposures from 2012 to 2023, 3,113 before the 2021 weight-management approval and 6,920 after, with the share managed in or referred to a health care facility rising from 23.0% to 33.5% (Journal of Medical Toxicology, February 2026). An earlier study found the case rate per million US population rose from 1.16 in 2017 to 6.32 in 2022 (Journal of Medical Toxicology, February 2024).

Anti-doping. WADA-accredited labs analyzed 72,259 urine samples for growth hormone releasing factors in 2024, up from 58,549 in 2023, and reported an adverse analytical finding rate of 0.78% across 297,965 samples (WADA 2024 Testing Figures, December 2025).

Outside the US. In a 2015 survey of 438 bodybuilders in Hamedan, Iran, 12.6% reported using peptide hormones and growth factors, the second most used category after steroid derivatives (Zahedan Journal of Research in Medical Sciences, 2017). It is the only peer-reviewed prevalence figure for non-prescription peptide use we found, and it is old and local. No US survey isolates research-peptide use.

How this page is maintained

Every link was loaded and every figure matched to its page on September 13, 2026, using a script that fetches each source and checks the number is present. Where a source blocks automated fetches, a person read the page. We refresh the page quarterly: registry counts are re-run, bill status is re-checked, new Lilly and Novo Nordisk quarters are added, and new FDA advisory actions are logged. Corrections go to the address on our contact page. If you spot a number that no longer matches its source, tell us and we will fix it and note the change here.

FAQ

Is BPC-157 FDA approved?

No. BPC-157 has no FDA approval for any use. In July 2026, FDA staff proposed not adding it to the 503A compounding list, citing incomplete characterization and missing safety data, and the compound was withdrawn from the Category 2 list in April 2026. Details and links are in the regulation section above.

How many peptide drugs has the FDA approved?

Around 100 since insulin in 1921, per a 2024 peer-reviewed review. A separate review counts 34 peptide approvals between 2016 and 2024. The two counts use different windows.

How big is the research peptide market?

No peer-reviewed estimate exists. The only measured slice is crypto payments, which Chainalysis put above a $100 million annual run rate by mid-2026. Card and bank payments are not counted in that figure. Widely repeated vendor revenue numbers trace to one private analytics firm and have no primary source.

Are research peptides banned in sport?

BPC-157 is listed under S0 and TB-500 under S2.3 on the WADA 2026 Prohibited List, both prohibited at all times. USADA has sanctioned athletes for BPC-157 use with bans from four months to four years.

How many vendors publish a certificate of analysis for every lot?

Nine of the 33 vendors listed on Peptide Source Tracker as of August 29, 2026. Fifteen confirm third-party testing of some kind.